evipedia.ai
← Back

Forskolin for Health & Longevity

Evidence Review created on 11/03/2026 using AI4L / Opus 5.5

Also known as: Colforsin, Coleonol, Coleus forskohlii, Coleus forskohlii Extract, Plectranthus barbatus, Coleus barbatus, Plectranthus forskohlii, Indian Coleus, Makandi, Pashanabhedi, HL-362, ForsLean, Forcslim

Motivation

Forskolin is a natural compound taken from the root of Indian coleus, a mint-family plant long used in traditional Indian medicine. It is sold as a root extract, usually labelled with its forskolin content. Its appeal rests on a single action: it switches on an enzyme that raises a messenger molecule many cells use to burn fat, relax muscle and regulate hormones.

Laboratory scientists have used forskolin since the early 1980s as a standard research tool, and drug developers later derived medicines from it. The extract later entered the supplement market, where it gained wide attention as a fat-loss product after television promotion in 2014. Small human studies have looked at body composition, eye pressure in glaucoma and asthma control, while health authorities in Japan began tracking side-effect reports from users.

This review examines what human and laboratory evidence shows about oral forskolin and its root extract for adults seeking to improve health and extend healthy lifespan. It weighs the reported benefits against known and suspected risks, drug interactions and product-quality problems, and sets out the protocols that studies have used.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and narrative reviews that give a high-level overview of forskolin’s uses, mechanism, and evidence.

No forskolin content was found from Rhonda Patrick, Peter Attia, Andrew Huberman or Chris Kresser: their site searches and targeted web searches returned no article, episode or post discussing forskolin. Lifespan.io mentions forskolin only briefly, as a minor ingredient in cell-reprogramming cocktails and in a one-paragraph report of its mouse lifespan result, so four items are listed rather than five.

Grokipedia

  • Forskolin

    A dedicated article covering forskolin’s discovery, biosynthesis, chemistry and mechanism, its weight-loss and other medical uses, and its side effects, drug interactions and dosage.

Examine

  • Coleus forskohlii

    Summarizes six small human trials, the common 250 mg twice-daily extract dose, and cautions on low blood pressure, stomach acid and platelet inhibition.

ConsumerLab

Systematic Reviews

This section lists the systematic reviews that evaluate forskolin-containing supplements in human trials.

No systematic review or meta-analysis addresses forskolin’s principal risks (digestive effects, liver signals and drug-metabolism induction); Nikkhah 2026 covers safety only through adverse events reported in its four efficacy trials.

Mechanism of Action

Forskolin is a labdane diterpene (a plant compound built from four isoprene units) that binds directly to adenylyl cyclase (a membrane enzyme), which converts adenosine triphosphate (the cell’s energy molecule) into cAMP (cyclic adenosine monophosphate, a messenger molecule inside cells) (Seamon 1981). Unlike adrenaline, it bypasses cell-surface receptors, so it can raise cAMP in almost every tissue.

Raised cAMP activates protein kinase A (PKA, an enzyme that switches other proteins on or off) and EPAC (exchange protein activated by cAMP, a second cAMP sensor). Proposed downstream effects include:

  • Fat breakdown: PKA activates hormone-sensitive lipase (the enzyme that releases stored fat) in fat cells.
  • Smooth-muscle relaxation: relaxation of airway and blood-vessel muscle explains bronchodilation (airway widening) and blood-pressure lowering.
  • Eye pressure: cAMP alters fluid handling in the ciliary body (eye tissue that produces internal fluid).
  • Platelets: cAMP blocks platelet clumping.
  • Testosterone: cAMP carries the signal of luteinizing hormone (the pituitary hormone that tells the testes to make testosterone).

A competing, cAMP-independent route: forskolin and a non-cyclase-activating analogue both activate PXR (pregnane X receptor, a liver sensor that switches on drug-metabolizing enzymes), inducing CYP3A4 (the liver enzyme that clears about half of prescription drugs) (Ding 2005). Mouse work attributes liver enlargement and fatty liver to other extract constituents, not forskolin (Virgona 2012; Umegaki 2019).

Oral pharmacokinetics in humans (absorption, half-life, tissue distribution and metabolic pathway) have not been published. The intravenous derivative colforsin daropate has a metabolic half-life of about 1.9 hours (Kikura 2004).

Historical Context & Evolution

Coleus forskohlii (now classified as Plectranthus barbatus) has been used in Ayurvedic and African folk medicine for digestive complaints, heart and respiratory disorders, and convulsions; in India the root is also pickled as food (review: Alasbahi 2010).

In the 1970s, Indian researchers screening medicinal plants for blood-pressure activity isolated forskolin (first called coleonol), which lowered blood pressure in animals (Dubey 1981). In 1981 it was shown to activate adenylyl cyclase directly, and it became one of biology’s most widely used laboratory tools (Seamon 1981).

Clinical development followed two routes. Topical eye drops lowered eye pressure in volunteers (Caprioli 1983), but a later study found no effect on fluid production (Brubaker 1987). Intravenous forskolin improved heart output in heart-failure patients (Baumann 1990), leading to the water-soluble derivative colforsin daropate.

Interest in health optimization arose in the 2000s when supplement manufacturers marketed standardized root extract for fat loss after two small trials of Sabinsa’s ForsLean extract, one in men reporting fat loss (Godard 2005) and one in women finding none (Henderson 2005; product supplied by its maker, Sabinsa). Television promotion in 2014 drew wide attention and critical commentary (Science-Based Medicine, Hall 2014). Since then, further trials have added mixed body-composition results, and Japanese surveillance of adverse events shifted attention towards safety; the evidence remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every human outcome comes from small trials by single research groups, or from conflicting trials, and no outcome has been replicated by independent groups without contrary results.

Medium 🟩 🟩

Body Fat and Body Weight ⚠️ Conflicted

Four 12-week placebo-controlled trials tested 250 mg of 10% extract twice daily. Godard 2005 (University of Kansas, 30 men) found less fat mass than placebo by DXA (dual-energy X-ray absorptiometry, a body-composition scan). Henderson 2005 (Baylor University, 19 women) and Loftus 2015 (Victoria University, 30 adults; extract supplied by maker Olive Lifesciences) found no clear difference; Channangihalli Thimmegowda 2026 (60 adults, allocated non-randomly; authors employed by maker Star Hi Herbs) reported greater weight loss than placebo. Net reading: a small, inconsistent fat-loss effect.

Magnitude: Body weight fell 1.93 kg with extract and 1.03 kg with placebo over 12 weeks; the difference in change over time between groups was statistically significant (group-by-time interaction p < 0.001, where p is the probability of a difference this large arising by chance), and no confidence interval (the range likely to contain the true effect) was reported (Channangihalli Thimmegowda 2026; its abstract presents the 1.93 kg as the difference from placebo, but the full-text table shows it is the within-group change); body mass −0.7 kg with extract versus +1.0 kg with placebo, not statistically significant (Henderson 2005).

Asthma Attack Prevention

Oral forskolin (10 mg daily) was compared with preventive inhalers in mild-to-moderate persistent asthma. Over 6 months fewer forskolin patients than cromolyn (a mast-cell stabilizer that blocks allergy-cell activation) patients had any attack (González-Sánchez 2006). Against beclomethasone (an inhaled corticosteroid, a steroid that calms airway inflammation) over 2 months, lung function did not improve with forskolin, and attacks were rare in both groups (Huerta 2010). Both small, single-blind (patients unaware of their treatment), placebo-free trials come from one University of Colima group.

Magnitude: 40% of forskolin patients versus 85% of cromolyn patients had asthma attacks over 6 months (8/20 versus 17/20), no confidence interval reported (González-Sánchez 2006).

Free Testosterone in Men

In overweight and obese men, 12 weeks of 250 mg extract twice daily raised serum free testosterone significantly versus placebo; total testosterone rose but not significantly (Godard 2005). The proposed mechanism is cAMP-driven stimulation of testosterone-producing cells. This is a single 30-person trial, the finding was a secondary outcome, and no study has measured testosterone in women or in men with normal weight.

Magnitude: Total testosterone +16.8% with extract versus −1.1% with placebo, difference not statistically significant; the free-testosterone rise was significant, but the abstract reports no figure (Godard 2005).

Bone Mass in Men

The same 12-week trial in 30 overweight men reported a significant gain in DXA-measured bone mass versus placebo (Godard 2005). cAMP stimulates bone-forming cells, and extract preserved bone in ovariectomized rats (ovaries removed, a menopause model) (Kulkarni 2023; co-authored by extract maker Pharmanza Herbal). In women, the comparable trial found no change in bone mineral density (Henderson 2005), so the finding is confined to men and rests on one trial.

Magnitude: Bone mass increased versus placebo over 12 weeks (statistically significant); the literature reports no outcome figure in the published abstract (Godard 2005).

Low 🟩

Eye Pressure Reduction in Glaucoma

An oral forskolin–rutin (a plant flavonoid) supplement further lowered eye pressure in open-angle glaucoma (optic-nerve damage linked to eye pressure) despite maximal drug treatment (Vetrugno 2012; maker Sooft Italia’s related registration NCT00864578 was withdrawn unenrolled). Evidence is indirect: only multi-ingredient supplements were tested, open-label (participants knew their treatment).

Magnitude: Eye pressure fell a further 10% from enrollment with the supplement, while the reference group on topical drugs alone stayed stable (not compared between groups) (Vetrugno 2012).

Insulin Sensitivity ⚠️ Conflicted

With a calorie-reduced diet, extract lowered fasting insulin and HOMA-IR (an insulin-resistance index from fasting glucose and insulin) versus placebo (Loftus 2015). A similar trial found no insulin change (Henderson 2005). Net reading: an unreplicated signal.

Magnitude: Fasting insulin fell from 9.6 to 6.1 mU/L with extract and rose from 6.8 to 8.5 mU/L with placebo (p = 0.001 for the difference between groups); HOMA-IR fell from 2.3 to 1.5 versus rising from 1.4 to 2.1 (p = 0.01), no confidence interval reported (Loftus 2015).

Blood Lipids ⚠️ Conflicted

A manufacturer-run trial’s abstract reports lower triglycerides (blood fats) and higher HDL cholesterol (high-density lipoprotein, which removes cholesterol from arteries), but its full text shows no significant difference from placebo (Channangihalli Thimmegowda 2026). Other maker-supplied trials found no lipid difference (Loftus 2015; Henderson 2005). Net reading: no reliable lipid effect.

Magnitude: Over 12 weeks, triglycerides fell 11.7 mg/dL with extract and 10.6 mg/dL with placebo, and HDL rose 2.2 versus 1.6 mg/dL; neither group difference was statistically significant (p = 0.388 and p = 0.075), no confidence interval reported (Channangihalli Thimmegowda 2026).

Heart Output in Heart Failure

Intravenous forskolin in 12 patients with NYHA class III (marked activity limitation) cardiomyopathy (weakened heart muscle) lowered filling pressures and raised stroke volume (blood pumped per beat) (Baumann 1990). Evidence is indirect: intravenous route, uncontrolled.

Magnitude: Stroke volume rose about 70% and pulmonary wedge pressure (pressure backing up into the lungs) fell by more than 50% during infusion (no control group) (Baumann 1990).

Post-COVID-19 Smell Recovery

In a randomized trial of 285 adults with persistent smell loss after COVID-19 (coronavirus disease 2019), the Sniffin’ Sticks score (a validated smell test) improved significantly within the forskolin group (Abdelazim 2024). No comparison with placebo is reported, so the gain cannot be separated from natural recovery.

Magnitude: Composite smell score improved significantly within the forskolin group, not compared between groups in the published abstract, which reports no outcome figure (Abdelazim 2024).

Speculative 🟨

Anticancer Activity

A review reports that raising cAMP with forskolin slows growth and migration of cancer cells and sensitizes them to chemotherapy in laboratory and animal studies (Sapio 2017). No human outcome data exist.

Liver Fat Reduction

Pure forskolin reduced fatty liver and scarring in high-fat-fed mice (Liu 2026), whereas whole extract blunted dietary improvement of fatty liver in mice (Suzuki 2020). Animal data only.

Memory Protection

In rats with diet-induced memory loss, forskolin improved maze performance and reduced brain inflammation and amyloid (Alzheimer-type protein) deposits (Kaur 2018). Animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants that alter forskolin response. Variants in adenylyl cyclase or CYP3A genes are plausible modifiers but untested.
  • Baseline biomarkers: Glaucoma patients with eye pressure of 21 mmHg or higher had a larger reduction (15%) than those below 21 mmHg (9%) (Vetrugno 2012). Body-composition trials enrolled only people with a body-mass index of 25 or more.
  • Sex: The only positive body-composition trial with DXA enrolled men (Godard 2005); the trial in women found no effect (Henderson 2005). Whether this reflects sex, sample size or chance is unknown.
  • Pre-existing conditions: Benefits were reported in people with overweight, persistent asthma, treated glaucoma, post-COVID-19 smell loss and heart failure. No trial enrolled healthy, lean, health-optimizing adults.
  • Age: Trials enrolled adults up to 65–70 years; no data exist for people over 70, whose bone, testosterone and eye-pressure baselines differ.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events come from small short trials and an uncontrolled user survey, and the liver and cardiovascular signals rest on case reports, animal data or an intravenous derivative.

Medium 🟥 🟥

No risk reaches Medium: the only controlled harm signal, loose stools in one small trial, is outweighed by a larger trial reporting no adverse events, and the other risks rest on an uncontrolled user survey, case reports, animal data or an intravenous derivative.

Low 🟥

Diarrhea and Loose Stools ⚠️ Conflicted

Loose stools appeared in the first three weeks of one small placebo-controlled trial (Loftus 2015) and dominated adverse events in a Japanese user survey, rising with dose (Nishijima 2019). A larger trial reported no adverse events (Channangihalli Thimmegowda 2026). Net reading: mild, dose-related digestive upset, unconfirmed in larger controlled data.

Magnitude: 2 of 15 participants on extract versus none of 15 on placebo (Loftus 2015); 10.5% of users reported any adverse event, 81% of them diarrhea (survey, no control group) (Nishijima 2019).

Liver Injury ⚠️ Conflicted

Japan labelled the extract a “designated ingredient” over adverse-effect risks (Chiba 2022); a study linked slimming-food liver injury to its CYP3A4 induction (Adachi 2024). One trial’s abstract reports no liver-enzyme change; its full text shows a significant, still-normal shift in one enzyme (Henderson 2005). Net reading: rare, product-dependent.

Magnitude: Over 12 weeks, ALT (alanine aminotransferase, a marker of liver-cell damage) rose from 26.0 to 27.8 U/L with extract and from 24.0 to 26.9 U/L with placebo; the group difference was not statistically significant (p = 0.288), no confidence interval reported (Channangihalli Thimmegowda 2026). No trial recorded clinical liver injury, and case and surveillance reports give no rates.

Low Blood Pressure and Rapid Heart Rate ⚠️ Conflicted

Intravenous forskolin dilates blood vessels and slightly raises heart rate (Baumann 1990); its derivative colforsin has caused tachycardia (fast heart rate) and arrhythmias (irregular rhythms) (Drugs.com forskolin monograph). Oral trials found no change (Henderson 2005). Net reading: indirect, unconfirmed orally.

Magnitude: Over 12 weeks of oral extract, systolic blood pressure went from 122.3 to 123.6 mmHg with extract and from 122.9 to 124.7 mmHg with placebo, and heart rate from 83.1 to 77.5 versus 82.6 to 77.3 beats per minute; neither group difference was statistically significant (p = 0.456 and p = 0.736), no confidence interval reported (Channangihalli Thimmegowda 2026).

Speculative 🟨

Accelerated Drug Clearance

Coleus forskohlii extract induced CYP3A4 in reporter cells and forskolin in humanized mice (carrying human genes) (Adachi 2024); an extract-maker (Olive Lifesciences) study found none in rat cells (Hebbani Nagarajappa 2016). No human data.

Bleeding Tendency

Forskolin blocks aggregation of human platelets in laboratory assays (Siegl 1982). No human bleeding events have been reported; the basis is mechanistic only.

Kidney Cyst Growth

Forskolin more than doubled proliferation of cyst cells from people with polycystic kidney disease (inherited growth of fluid-filled kidney cysts) in culture (Yamaguchi 2000). Laboratory data only; no human reports.

Cellular Senescence

Forskolin pushed human fat-derived stem cells into senescence (permanent growth arrest with inflammatory secretion) through mitochondrial oxidative stress (Wang 2023). Laboratory data only.

Risk-Modifying Factors

  • Genetic polymorphisms: Mutations in PKD1 or PKD2 (genes encoding polycystin proteins that keep kidney tubules from forming cysts) cause polycystic kidney disease, where cAMP drives cyst growth. No drug-metabolism variant has been studied for forskolin.
  • Baseline biomarkers: Low resting blood pressure, raised liver enzymes (ALT and AST, alanine and aspartate aminotransferase, markers of liver-cell damage) or a low platelet count at baseline leave less margin for the blood-pressure, liver and bleeding concerns.
  • Sex: No sex difference in side effects has been reported; trials in men and in women found similar tolerability. Pregnancy is a specific concern because embryo toxicity has been reported (Drugs.com forskolin monograph).
  • Pre-existing conditions: Polycystic kidney disease, fatty liver disease, peptic ulcer (stomach or duodenal ulcer), low blood pressure, heart-rhythm disorders and bleeding disorders plausibly raise risk; mouse data suggest extract worsens recovery from fatty liver (Suzuki 2020).
  • Age: Older adults more often take several CYP3A4-cleared medications and blood-pressure drugs, increasing interaction and dizziness risk; no trial enrolled people over 70.

Key Interactions & Contraindications

Documented interactions:

  • Topical glaucoma medications (timolol, latanoprost, dorzolamide): adding an oral forskolin–rutin supplement (maker Sooft Italia) lowered eye pressure a further 10% in patients already on these drops, an additive effect (Vetrugno 2012). Eye pressure is checked by the treating ophthalmologist after adding it.
  • Timolol (beta-blocker eye drops, which block adrenaline signalling to cut eye-fluid production): topical forskolin produced no change in eye-fluid production after timolol pretreatment, so no interaction was found (Brubaker 1987).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • CYP3A4 substrates (drugs cleared by CYP3A4: atorvastatin, simvastatin, amlodipine, apixaban, oral contraceptives): inferred from PXR-mediated CYP3A4 induction; lower drug levels and reduced effect. Separating doses does not prevent induction; drug levels or effect are rechecked after starting or stopping.
  • Narrow-margin CYP3A4 drugs (tacrolimus, cyclosporine, warfarin): inferred from CYP3A4 and CYP2C induction (CYP2C, liver enzymes that clear warfarin and many others); loss of drug effect, such as transplant rejection or clotting. Avoid.
  • Acetaminophen (paracetamol): inferred from CYP3A4 induction raising formation of its toxic metabolite; increased liver-injury risk at high doses. Acetaminophen intake is kept within label limits.
  • Antiplatelet and anticoagulant drugs (drugs that slow platelet clumping or blood clotting: aspirin, clopidogrel, apixaban, warfarin): inferred from forskolin’s cAMP-mediated platelet inhibition; additive bleeding risk. Bruising and bleeding are watched for, and use is stopped two weeks before surgery.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory painkillers: ibuprofen, naproxen): inferred from additive platelet inhibition and stomach irritation alongside forskolin’s acid-raising action; more bleeding and stomach upset. Use is kept occasional.
  • Blood-pressure-lowering drugs and nitrates (vessel-widening heart drugs) (amlodipine, lisinopril, nitroglycerin, sildenafil): inferred from additive blood-vessel relaxation; dizziness or fainting from low blood pressure. Home blood pressure is checked during the first weeks.
  • Beta-agonists and phosphodiesterase-3/4 inhibitors (airway openers and drugs that block cAMP breakdown: albuterol, cilostazol, roflumilast, theophylline): inferred from additive cAMP elevation; fast heart rate and palpitations. Heart rate is monitored when combining.
  • Supplements that slow platelet clumping or blood clotting (fish oil, ginkgo, garlic, vitamin E): inferred from additive platelet inhibition; increased bleeding tendency. All are paused two weeks before surgery.
  • Supplements that lower blood pressure (beetroot nitrate, magnesium, hawthorn): inferred from additive blood-vessel relaxation; additive blood-pressure lowering and dizziness. Home blood pressure is checked after adding.
  • Stimulant weight-loss supplements (caffeine, synephrine, yohimbine): inferred from additive cAMP and adrenaline-like signalling; fast heart rate and palpitations. Single-ingredient forskolin products avoid this combination.
  • Diabetes medications (metformin, insulin, sulfonylureas such as glipizide): inferred from cAMP-driven glucose release by the liver, which raised blood glucose in rats (Drugs.com forskolin monograph); weaker glucose control. Blood glucose is checked more often after starting.
  • Other enzyme-inducing supplements (St John’s wort): inferred from shared PXR activation; additive CYP3A4 induction and further loss of drug effect. Combined use is avoided in people taking prescription drugs.

Populations who should avoid Forskolin:

  • Pregnancy and breastfeeding: inferred from reported embryo-related toxicity and the plant’s traditional use to induce menstruation, as summarized in the Drugs.com monograph (Drugs.com forskolin monograph); no human data.
  • Polycystic kidney disease: inferred from cAMP-driven growth of human cyst cells in culture (Yamaguchi 2000) and a forskolin-like molecule in human cyst fluid (Putnam 2007), the latter the basis of Drugs.com’s avoidance advice (Drugs.com forskolin monograph); no human outcome data.
  • Organ-transplant recipients on tacrolimus or cyclosporine: inferred from CYP3A4 induction lowering drug levels; no human data.
  • Bleeding disorders or surgery within 2 weeks: inferred from platelet inhibition; no human data.
  • Active peptic ulcer: inferred from cAMP-stimulated stomach-acid secretion; no human data.
  • Low blood pressure (resting systolic below 90 mmHg) or symptomatic arrhythmia: inferred from vessel relaxation and heart-rate effects of intravenous forskolin; no oral data.
  • Fatty liver disease or raised liver enzymes: inferred from extract-induced fatty liver and impaired recovery in mice (Suzuki 2020); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low starting dose: one 250 mg extract capsule daily for 1–2 weeks before moving to twice daily limits the dose-related diarrhea reported by users (Nishijima 2019).
  • Extract dose ceiling: a Japanese safety analysis placed the lowest-diarrhea intake below 250 mg extract daily and suggested 500 mg daily (50 mg forskolin) might be acceptable (Nishijima 2019); staying at or below 500 mg limits digestive upset.
  • Medication review before starting: a pharmacist review of every prescription for CYP3A4 clearance, antiplatelet or blood-pressure effects prevents loss of drug effect, bleeding and low blood pressure.
  • Liver-enzyme check: ALT and AST at baseline and after 4–8 weeks, with use stopped if ALT exceeds 3 times the upper limit of normal, limits progression of rare extract-related liver injury.
  • Home blood pressure and pulse: daily readings for the first two weeks, with use stopped if systolic pressure falls below 90 mmHg or palpitations occur, prevent fainting and rhythm problems.
  • Pre-surgery pause: stopping 2 weeks before surgery or dental extraction removes additive platelet inhibition and bleeding risk.
  • Tested standardized products: third-party-tested extract standardized to 10% forskolin reduces the risk of mislabelled dose and of crude extracts carrying liver-active constituents (Umegaki 2019).
  • Single-ingredient products: single-ingredient forskolin rather than blends with caffeine or synephrine prevents additive fast heart rate and palpitations.

Therapeutic Protocol

Timing, cycling, and titration parameters below reflect common practice unless cited.

  • Standard body-composition protocol: 250 mg of root extract standardized to 10% forskolin (25 mg forskolin) twice daily for 12 weeks, as in all four trials (Godard 2005; Loftus 2015); popularized by The Dr. Oz Show (Science-Based Medicine, Hall 2014).
  • Lower-dose safety approach: Japanese National Institute of Health and Nutrition researchers estimated under 250 mg extract daily as the lowest-diarrhea intake, with 500 mg daily possibly acceptable (Nishijima 2019).
  • Supplement-seller approach: 10 mg forskolin daily from standardized extract, taken on an empty stomach, as given by Life Extension (Life Extension forskolin article); one-fifth of the trial dose and untested in body-composition trials.
  • Asthma protocol: 10 mg purified forskolin once daily orally for 2–6 months, used by the University of Colima group (González-Sánchez 2006).
  • Glaucoma add-on protocol: two tablets daily of a forskolin–rutin supplement alongside prescribed eye drops (Vetrugno 2012); exact forskolin content per tablet is not stated in the abstract.
  • Time of day: trials dosed 30 minutes before the morning and evening meals (Henderson 2005); common practice shifts the second dose to midday to avoid any stimulant effect at bedtime.
  • Half-life: oral half-life in humans is unknown; the intravenous derivative colforsin daropate has a metabolic half-life of about 1.9 hours but an elimination half-life of about 95 hours (Kikura 2004), so it does not settle dosing frequency.
  • Single versus split dose: split twice-daily dosing matches the body-composition trials; the asthma regimen used one daily dose.
  • Genetic polymorphisms: no pharmacogenetic data exist for dose choice; carriers of PKD1 or PKD2 mutations fall under the polycystic kidney disease avoidance group.
  • Sex differences: the DXA-measured fat-mass benefit appeared in men (Godard 2005) but not in women (Henderson 2005); a mostly female manufacturer trial reported greater weight loss than placebo (Channangihalli Thimmegowda 2026); trials used the same dose in both sexes.
  • Age: trials enrolled adults aged 18–70; in older adults the lower-dose approach is common practice because of medication interactions and blood-pressure effects.
  • Baseline biomarkers: benefits were studied at a body-mass index of 25 or more and, in glaucoma, at raised eye pressure; lean adults with normal eye pressure have no tested protocol.
  • Pre-existing conditions: in every asthma and glaucoma trial, forskolin was added to, not substituted for, established treatment.

Discontinuation & Cycling

  • Duration: all trials lasted 2 weeks to 6 months; forskolin is used short-term, with no data beyond 6 months supporting lifelong use.
  • Withdrawal effects: none reported. Eye-pressure reduction reversed within 40 days of stopping (Pescosolido 2010).
  • Tapering: not needed; no rebound effects are known. In mice, liver-enzyme induction reversed within one week of stopping extract (Virgona 2012).
  • Cycling: no study has tested cycling. Common practice uses 8–12-week courses followed by a break of several weeks to reassess benefit and allow enzyme induction to reverse.
  • Drug re-checks after stopping: stopping forskolin may raise levels of CYP3A4-cleared drugs as induction fades; drug levels or effects are rechecked 1–2 weeks after stopping.

Sourcing and Quality

  • Standardization: products range from purified forskolin to crude root powder; trials used root extract standardized to 10% forskolin, so labels stating both extract amount and forskolin milligrams allow dose matching.
  • Label accuracy: ConsumerLab found forskolin content from 1.9 to 50 mg per serving, and one product contained under 5% of its claimed forskolin (ConsumerLab weight-loss supplements review).
  • Extract constituents: in mice, fatty liver was likely caused by a non-forskolin constituent, 14-deoxycoleon U (Umegaki 2019); highly purified forskolin may carry less liver risk than crude extract.
  • Third-party testing: ConsumerLab approval and USP (United States Pharmacopeia) or NSF (an independent certification body) seals verify identity and labelled content.
  • Trial-tested ingredients: ForsLean (Sabinsa) and Forcslim (Star Hi Herbs) are the branded extracts used in published trials; both makers funded or supplied their trials.
  • Blends: “fat burner” blends often add caffeine or synephrine and seldom disclose forskolin content.
  • Future sources: yeast-based biosynthesis of forskolin has been demonstrated (Pateraki 2017), which could supply forskolin free of other root constituents.

Practical Considerations

  • Time to effect: eye-pressure reduction appeared within 1 week (Vetrugno 2012); body-composition changes were measured at 12 weeks; digestive effects appear in the first 3 weeks.
  • Common pitfalls: confusing extract milligrams with forskolin milligrams; expecting weight loss without dietary change; combining with stimulant blends; overlooking interactions with CYP3A4-cleared medications.
  • US regulatory status: sold as a dietary supplement, which the FDA (US Food and Drug Administration) does not approve before marketing (FDA dietary supplement questions and answers).
  • Enforcement history: the FTC (Federal Trade Commission) settled charges against marketers of “Pure Forskolin Extract” and other products for false weight-loss claims and fake celebrity endorsements (FTC press release).
  • Japan: after assessing adverse-effect risks in health foods, the Japanese government labelled Coleus forskohlii a “designated ingredient” (Chiba 2022).
  • Funding bias: no institutional payer covers supplements, and most trials were supplied or run by extract makers; independent long-term trials are scarce.
  • Cost: inexpensive; ConsumerLab found 25 mg forskolin costing $0.33–1.40 (ConsumerLab weight-loss supplements review).

Interaction with Foundational Habits

  • Sleep: None measured in trials; possibly indirect stimulation. Intravenous forskolin produced transient mood elevation and stimulation in a small uncontrolled study (Bersudsky 1996); dosing before breakfast and lunch rather than late evening avoids any potential sleep disruption.
  • Nutrition: Indirect, no added benefit shown with dieting. Combined with a 500 kcal/day deficit, extract gave no extra weight or waist loss over placebo (Loftus 2015). Taking it 30 minutes before meals matches trials; no nutrient depletion is known.
  • Exercise: None studied in humans; mechanistically potentiating. Forskolin mimics the adrenaline-driven cAMP signal that mobilizes fat during exercise; one trial reported a non-significant lean-mass gain in men (Godard 2005). In mice, enzyme induction was greater with diet than exercise (Suzuki 2020).
  • Stress management: Indirect. Forskolin raises cAMP, the same messenger used by stress hormones; women taking extract trended toward less fatigue, without mood changes (Henderson 2005). No human cortisol data exist.

Monitoring Protocol & Defining Success

Baseline testing before starting covers liver enzymes, blood pressure and resting heart rate as safety checks, and the markers the user intends to change: body weight, waist circumference and, where available, a DXA body-composition scan. Men tracking hormonal effects add free testosterone, people with glaucoma add an eye-pressure measurement, and anyone on CYP3A4-cleared, antiplatelet or anticoagulant medication reviews drug levels or clotting tests with the prescriber.

Ongoing monitoring follows this cadence: blood pressure and heart rate daily for the first 2 weeks, liver enzymes at 4–8 weeks, then body measurements, metabolic markers and eye pressure at 12 weeks, when trials measured their outcomes. If no meaningful change from the individual’s own baseline appears by 12 weeks, the course is judged unsuccessful. Laboratory tests are repeated every 6–12 months during continued use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT and AST ALT 0–44 U/L, AST 0–40 U/L (standard reference range) Safety check: rise stops use Fasting not required; stop if ALT exceeds 3 times the upper limit of normal; pair with GGT (gamma-glutamyl transferase, another liver enzyme) if raised
Blood pressure Below 120/80 mmHg, per the 2017 ACC/AHA guideline Safety check: low readings stop use Source: Whelton 2018 (ACC/AHA: American College of Cardiology/American Heart Association; their clinician members are paid to diagnose and treat high blood pressure, so lower targets widen their patient base); seated, rested, morning home readings; conventional reference range 90–120/60–80 mmHg
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: rise or palpitations stop use Measure seated after 5 minutes of rest, same time daily
Body weight and waist circumference No established target; track change from own baseline Expected to change Measure fasting, morning, same scale and tape position
Body-fat percentage (DXA) No established target; track change from own baseline Expected to change Same scanner and hydration state each time
Fasting insulin and HOMA-IR Fasting insulin 2.6–24.9 mU/L (standard reference range) Expected to change 10–12 hour fast; pair with fasting glucose to compute HOMA-IR, which has no conventional reference range (track change from own baseline); ranges vary by laboratory
Free testosterone (men) 52–280 pg/mL in adult men by equilibrium dialysis (standard reference range) Expected to change Draw before 10 a.m.; measured directly or calculated from total testosterone and SHBG (sex hormone-binding globulin, a blood protein that binds testosterone); ranges vary by laboratory and method
Eye pressure (glaucoma users) 10–21 mmHg (standard reference range) Expected to change Measured by an ophthalmologist; individual glaucoma targets are set lower

Qualitative markers:

  • Stool frequency and consistency: loose stools in the first 3 weeks signal dose reduction.
  • Palpitations, dizziness or light-headedness: signal blood-pressure or heart-rate effects.
  • Easy bruising or prolonged bleeding: signals additive platelet inhibition.
  • Energy and fatigue: subjective energy levels across the course.
  • Appetite and fullness: changes in hunger before meals.
  • Asthma symptoms (asthma users): frequency of attacks and rescue-inhaler use.
  • Sense of smell (post-COVID-19 users): ability to identify everyday odors.

Emerging Research

  • No ongoing trials: a ClinicalTrials.gov search on 2026-11-03 found no recruiting or active trial of oral forskolin; the evidence base will therefore change slowly, and short-term manufacturer trials remain the main source.
  • Completed appetite trial: NCT02143349, an Olive Lifesciences-sponsored trial of 250 mg extract twice daily for 12 weeks (appetite primary endpoint); registry status unknown, but published as Loftus 2015: no appetite or body-measurement difference versus placebo, lower fasting insulin.
  • Withdrawn glaucoma trials: NCT00864578 and NCT00863811, sponsored by Sooft Italia to test oral forskolin on eye pressure, were withdrawn before enrolling anyone. A 10-patient placebo-controlled trial found oral forskolin plus rutin blunted eye-pressure spikes after laser iris surgery (Nebbioso 2012); no placebo-controlled trial in glaucoma exists.
  • Smell recovery replication: the single 285-person trial (Abdelazim 2024) reports no placebo comparison and awaits independent replication; a trial showing a difference from placebo would raise this benefit’s grade, a null one would leave it unsupported.
  • Human drug-interaction studies: CYP3A4 induction in humanized mice (Adachi 2024) has not been tested in people; a positive human study would make these interactions documented and strengthen avoidance advice.
  • Body-composition trials: the 2026 systematic review called for longer, larger trials (Nikkhah 2026); an independent positive trial would firm up fat-loss claims, while further null trials would weaken them.
  • cAMP and aging biology: in the National Institute on Aging mouse lifespan program, forskolin did not significantly extend lifespan; the authors suggest a non-significant male trend might strengthen at other doses (Strong 2026); it also induced senescence in human stem cells (Wang 2023), while animal liver and memory studies point the other way.

Conclusion

Forskolin is a plant compound from the root of Indian coleus that switches on a messenger system used by almost every cell. It is sold mainly as a fat-loss supplement, though it has also been studied for airway, eye and heart conditions.

For health-focused adults, the human evidence is thin. The most-studied claim, fat loss, rests on a handful of small, short trials that disagree with one another, and most were supplied or run by extract makers. Single trials or single research groups suggest fewer asthma attacks and higher testosterone and bone mass in overweight men, but none has been repeated. Effects on eye pressure, smell recovery after viral illness, blood sugar handling and blood fats are weaker still. No human study has measured effects on aging, a mouse lifespan test found no clear gain, and laboratory work points both ways.

The main known side effect is mild, dose-related diarrhea early in use. Less certain but more serious concerns include rare liver injury, reported mainly with whole-root products in Japan, faster breakdown of many common medicines, slower blood clotting and lower blood pressure. Product quality varies widely, with some products containing almost none of the labelled compound.

Overall, forskolin is an inexpensive, generally well-tolerated supplement whose benefits for long-term health remain unproven and whose drug-interaction potential matters most for people taking several medicines.

Top - Benefits - Risks - Protocol